EmCyte Corp. v. Apex Biologix

CourtDistrict Court, M.D. Florida
DecidedFebruary 9, 2022
Docket2:19-cv-00769
StatusUnknown

This text of EmCyte Corp. v. Apex Biologix (EmCyte Corp. v. Apex Biologix) is published on Counsel Stack Legal Research, covering District Court, M.D. Florida primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
EmCyte Corp. v. Apex Biologix, (M.D. Fla. 2022).

Opinion

UNITED STATES DISTRICT COURT MIDDLE DISTRICT OF FLORIDA FORT MYERS DIVISION

EMCYTE CORP.,

Plaintiff,

v. Case No: 2:19-cv-769-JES-NPM

XLMEDICA, INC., and ANNA STAHL,

Defendants,

Counter-Plaintiffs,

v.

Counter-Defendant,

And

PATRICK PENNIE,

Third Party-Defendant.

_______________________________

OPINION AND ORDER This matter comes before the Court on review of plaintiff’s Omnibus Motion to Dismiss Amended Counterclaims and Strike Affirmative Defenses, Immaterial, Scandalous Allegations, and Improper Answers (Doc. #124) filed on August 6, 2021. This motion seeks to (1) strike portions of the Amended Answer; (2) strike all of the affirmative defenses; (3) strike portions of the Counterclaim; and (4) dismiss two counts of the Counterclaim. Defendants/Counter-Plaintiffs filed a Response in Opposition (Doc. #125) on August 17, 2021. For the reasons set forth below, the motion is granted in part and denied in part. I.

In a prior Opinion and Order (Doc. #109), the Court gave an overview of plaintiff’s allegations in this case. Plaintiff EmCyte Corporation (Plaintiff or EmCyte) initiated this lawsuit against defendants XLMedica, Inc., Anna Stahl, and Apex Biologix, LLC (collectively Defendants, or individually XLMedica, Stahl, or Apex). (Doc. #1). The Second Amended Complaint (Doc. # 22) (SAC) alleges that EmCyte is the world leader in Platelet Rich Plasma (PRP) and Progenitor Stem Cell Biologics. (Doc. #22, ¶ 1.) For over 20 years, EmCyte has manufactured blood concentrating systems, and develops, improves, and commercializes state-of-the-art devices used in preparing autologous platelet rich plasma from blood samples and bone marrow. (Id. at ¶¶ 12-13, 15.) The SAC alleges that Plaintiff’s blood concentrating systems include the PURE PRP® SupraPhysiologic (PURE PRP) and PURE BMC™ SupraPhysiologic (PURE BMC) products, both of which are protected under federal, state, or common law trademark and unfair competition laws. (Id. at ¶¶ 14, 16(Figure 1), 17, 19(Figure 2), 20(Figure 3), 27.) Plaintiff has continuously and extensively promoted its trademarked products in interstate commerce in connection with blood concentrating products since March 13, 2012. (Id. at ¶¶ 22, 24.) The SAC further alleges that defendant Stahl, a former EmCyte employee and distributor, founded XLMedica to directly compete with EmCyte. (Doc. #22, ¶¶ 38, 41-45.) Stahl and XLMedica undertook a multifaceted trademark infringement and unfair competition campaign squarely aimed at EmCyte and its customers by selling products offered under infringing marks, i.e. PURE PRP KIT and PURE BMA CONCENTRATION KIT, or confusingly similar variants (Infringing Marks) that usurp the goodwill associated with EmCyte’s trademarks. (Id. at ¶¶ 43-45, 51 (Figures 6 and 7.)) The SAC sets forth the following remaining claims: trademark infringements in violation of 15 U.S.C. § 1114 (Count I); contributory trademark infringements under § 1114 and common law (Count II); unfair competition under the Lanham Act, 15 U.S.C. § 1125(a) (Count III); common law unfair competition (Count IV); infringement of Florida TM No. T19000001087 (Count V). Plaintiff seeks injunctive relief to prohibit XLMedica and Stahl from using the Infringing Marks and engaging in unfair competition, a declaratory judgment related to its trademarks, compensatory and punitive damages, and reasonable attorney’s fees. (Id., pp. 24-26.) (Doc. #109, pp. 1-3.) This Opinion and Order denied a motion to dismiss the SAC. In due course Defendants filed an Amended Answer and Counterclaim With Demand For Jury Trial and Injunctive Relief (Doc. #123), which included an Answer, a three-count First Amended Counterclaim (the Counterclaim), and nine affirmative defenses. Defendants’ Counterclaim asserts counts alleging: (1) entitlement to a declaratory judgment of invalidity and cancellation; (2) tortious interference with advantageous business relationship; and (3) abuse of process. (Id., pp. 18-21.) Plaintiff now moves to dismiss the second and third counts of the Counterclaim for failing to state a claim. Plaintiff also seeks to strike all of Defendants’ affirmative defenses, and certain improper answers and immaterial facts contained in the Amended Answer. (Doc. #124, p. 2.) Defendants respond that they have adequately pled the counts in their Counterclaim, and that

neither their affirmative defenses nor the other allegations should be stricken since they are neither frivolous nor invalid as a matter of law. (Doc. #125, pp. 2, 10-11.) The Court will address Plaintiff’s motion to strike portions of the Amended Answer, the affirmative defenses, and the Counterclaim, and then the motion to dismiss the Counterclaim. II. Federal Rule of Civil Procedure 12(f) provides that a "court may strike from a pleading an insufficient defense or any redundant, immaterial, impertinent or scandalous matter." Fed. R. Civ. P. 12(f). "An allegation is 'impertinent' or 'immaterial'

when it is neither responsive nor relevant to the issues involved in the action." Sprengle v. Smith Mar. Inc., No. 3:20-cv-1348-MMH- JRK, 2021 U.S. Dist. LEXIS 94974, at *6 (M.D. Fla. May 19, 2021). "'Scandalous’ generally refers to any allegation that unnecessarily reflects on the moral character of an individual or states anything in repulsive language that detracts from the dignity of the court." Id. (citation omitted). “The purpose of a motion to strike is to clean up the pleadings, streamline litigation, and avoid unnecessary forays into immaterial matters.” Hutchings v. Fed. Ins. Co., No. 6:08-cv-305-Orl-19KRS, 2008 U.S. Dist. LEXIS 75334, 2008 WL 4186994, at *2 (M.D. Fla. Sept. 8, 2008). A motion to strike is often denied "unless the matter sought to be omitted has no possible relationship to the

controversy, may confuse the issues, or otherwise prejudice a party." Bank of Am., N.A. v. GREC Homes IX, LLC, No. 13-21718, 2014 U.S. Dist. LEXIS 8316, at *14 (S.D. Fla. Jan. 23, 2014) (internal quotations and citations omitted). A. Improper Answers To SAC Allegations EmCyte argues that Defendants provided ambiguous answers to the allegations in paragraphs 21, 27, 29-32, 34-37, 40, 45, and 119 of the SAC. (Doc. #124, pp. 19-20.) Specifically, EmCyte takes exception to Defendants’ answers stating that “to the extent an allegation sought to paraphrase or characterize the contents of a written document, the document speaks for itself and Defendants

deny any allegations to the extent they are inconsistent with that document”, or that certain allegations “state legal conclusions to which no answer is required” or “speak for themselves.” Plaintiff argues that these answers should be stricken and properly amended. (Id.) Defendants respond that EmCyte’s accusations overlook the entirety of Defendants’ responses, which comply with Rule 8(b)(3). (Doc. #125, pp. 17-18.) Rule 8(b) gives a party only three ways to respond to an allegation in a complaint: (1) admit the allegation; (2) deny the allegation; or (3) state that the party lacks knowledge or information sufficient to form a belief about the truth of the allegation. See Fed. R. Civ. P. 8(b)(1)(B), 8(b)(5); RE/MAX, LLC v. Prop. Professionals of Tampa Bay, Inc., No. 8:14-cv-419-T-

33TGW, 2014 U.S. Dist. LEXIS 55667, at *2 (M.D. Fla. Apr. 22, 2014).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Edwards v. Prime, Inc.
602 F.3d 1276 (Eleventh Circuit, 2010)
Cramer v. State of Florida
117 F.3d 1258 (Eleventh Circuit, 1997)
Erickson v. Pardus
551 U.S. 89 (Supreme Court, 2007)
Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
Eloy Rojas Mamani v. Jose Carlos Sanchez Berzain
654 F.3d 1148 (Eleventh Circuit, 2011)
Cazares v. Church of Scientology of Cal., Inc.
444 So. 2d 442 (District Court of Appeal of Florida, 1983)
Della-Donna v. Nova University, Inc.
512 So. 2d 1051 (District Court of Appeal of Florida, 1987)
Ethan Allen, Inc. v. Georgetown Manor
647 So. 2d 812 (Supreme Court of Florida, 1994)
Marty v. Gresh
501 So. 2d 87 (District Court of Appeal of Florida, 1987)
S & I Investments v. Payless Flea Market, Inc.
36 So. 3d 909 (District Court of Appeal of Florida, 2010)
Miami Herald Publishing Co. v. Ferre
636 F. Supp. 970 (S.D. Florida, 1985)
Smith v. Ocean State Bank
335 So. 2d 641 (District Court of Appeal of Florida, 1976)
Valdes v. GAB Robins North America, Inc.
924 So. 2d 862 (District Court of Appeal of Florida, 2006)
Peckins v. Kaye
443 So. 2d 1025 (District Court of Appeal of Florida, 1983)

Cite This Page — Counsel Stack

Bluebook (online)
EmCyte Corp. v. Apex Biologix, Counsel Stack Legal Research, https://law.counselstack.com/opinion/emcyte-corp-v-apex-biologix-flmd-2022.